Advertisement
PPBT vs SNTI
Which Stock Would AI Choose? Purple Biotech (PPBT) vs. Senti Biosciences (SNTI) Stock Comparison
Key Takeaways
- PPBT and SNTI are both clinical-stage, micro-cap biotechnology companies, but their recent momentum and near-term risk profiles diverge sharply.
- PPBT trades above the $1.00 Nasdaq minimum bid threshold and has recent patent and clinical-data catalysts, while SNTI has received a Nasdaq non-compliance notice and faces a going-concern warning.
- Tickeron AI Verdict: PPBT — its trend consistency, above-$1.00 positioning, and nearer-term catalysts currently outweigh SNTI's setup.
- Both names carry elevated downside risk typical of pre-revenue biotechs with limited cash runways and ongoing dilution pressure.
- For deeper coverage, explore PPBT Major News, PPBT Today's Price Move, SNTI Major News, and SNTI Today's Price Move.
- To see how AI-driven strategies are currently positioned across the market, visit the Trending AI Robots page.
Introduction
Investors evaluating small-cap oncology and cell-therapy names often weigh clinical catalysts against balance-sheet durability. This stock comparison examines PPBT (Purple Biotech Ltd.) and SNTI (Senti Biosciences Holdings, Inc.), two Nasdaq-listed clinical-stage biotechnology companies with sub-$20 million market capitalizations. Both develop next-generation cancer treatments and remain pre-revenue, meaning their share prices are driven primarily by trial data, regulatory milestones, and financing news rather than earnings. Traders and investors focused on high-volatility biotech opportunities, catalyst-driven momentum, and relative positioning may find this comparison useful for understanding how two superficially similar micro-caps are performing quite differently in the current environment.
PPBT Overview and Recent Performance
PPBT (Purple Biotech Ltd.) is an Israel-based clinical-stage oncology company developing therapies to overcome tumor immune evasion and drug resistance. Its pipeline includes CM24, a monoclonal antibody being studied with PD-1 checkpoint inhibitors in pancreatic cancer, NT219 in Phase 2 trials, and the CAPTN-3 multispecific antibody platform anchored by IM1240.
Recent market activity has been positive for PPBT. In recent weeks the company announced that an IM1240 abstract was selected for oral presentation at a major cancer research symposium, and earlier it received a Notice of Allowance from the U.S. Patent and Trademark Office covering its CAPTN-3 platform, a development that triggered a sharp single-day rally. Analysts have maintained a Buy rating with a $17 price target. The shares have traded above the $1.00 Nasdaq minimum bid threshold, and the 52-week range reflects both a prior decline and recent recovery. Sentiment has been supported by intellectual-property progress and upcoming data exposure, even as the company's modest cash position remains a key consideration.
SNTI Overview and Recent Performance
SNTI (Senti Biosciences Holdings, Inc.) is a clinical-stage biotechnology company based in South San Francisco developing cell and gene therapies using its Gene Circuit platform. Its lead candidate, SENTI-202, is a logic-gated "off-the-shelf" CAR-NK cell therapy for relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML), and it has received FDA designations including RMAT (Regenerative Medicine Advanced Therapy).
In recent weeks, SNTI has navigated a more difficult setup. The company received a Nasdaq non-compliance notice related to both its sub-$1.00 bid price and a stockholders' equity deficit, and it has disclosed a going-concern warning alongside a strategic transaction to sharpen its focus on genetic medicines. While positive Phase 1 data, FDA regulatory feedback, and an analyst Buy rating with a $12 price target provide fundamental support, the stock has traded well below $1.00 amid financing, delisting, and cash-runway concerns. These factors have pressured sentiment despite the pipeline's clinical promise.
Trending AI Robots
For traders who prefer a systematic, data-driven approach to navigating names like PPBT and SNTI, Tickeron's Trending AI Robots page offers a curated view of AI trading bots. Tickeron hosts hundreds of AI-powered trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and watchlist of securities. Because market conditions change constantly, only the bots best suited to the current environment earn a place in this curated Trending AI Robots section. Reviewing the Trending AI Robots list can help traders identify which automated strategies are currently demonstrating the strongest alignment with prevailing market dynamics.
Head-to-Head Comparison
Despite both being clinical-stage biotechs, PPBT and SNTI differ on several dimensions. In terms of business model, PPBT focuses on antibody-based oncology immunotherapies, while SNTI is built around engineered cell and gene therapies. Growth drivers also diverge: PPBT's near-term catalysts center on patent milestones and clinical data presentations, whereas SNTI's hinge on a pivotal trial design and financing execution.
Risk profiles contrast meaningfully. SNTI faces immediate delisting risk, a going-concern warning, and a strategic restructuring, representing higher structural uncertainty. PPBT maintains Nasdaq compliance but still carries limited cash and dilution risk. On momentum, PPBT has shown firmer recent relative performance and above-$1.00 positioning, while SNTI remains depressed below the minimum bid threshold. Both are highly volatile and share broad biotech sector exposure.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would currently favor PPBT. The stock's above-$1.00 Nasdaq positioning, recent patent allowance, upcoming data presentation, and firmer trend consistency contrast with SNTI's sub-$1.00 price, non-compliance notice, going-concern warning, and heavier structural uncertainty. While both names are speculative and volatile, PPBT currently presents the more constructive mix of catalysts and relative positioning. This assessment reflects probabilistic, trend-based analysis rather than a definitive prediction and should be viewed as one input among many.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PPBT is a Buy and SNTI is a Hold.
PPBT's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for PPBT turned positive on October 30, 2026. Looking at past instances where PPBT's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on PPBT as a result. In 63 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
PPBT moved above its 50-day moving average on November 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPBT advanced for three days, in 169 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
PPBT broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PPBT entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.172) is normal, around the industry mean (3.498). P/E Ratio (-0.027) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. PPBT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PPBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SNTI in -12.12% downward trend, declining for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SNTI declined for three days, in 273 of 312 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNTI as a result. In 79 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Aroon Indicator for SNTI entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SNTI's RSI Indicator exited the oversold zone, 36 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for SNTI just turned positive on November 11, 2026. Looking at past instances where SNTI's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
Following a +16.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNTI advanced for three days, in 194 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SNTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.465) is normal, around the industry mean (3.498). P/E Ratio (-0.095) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (166.667) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. SNTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
PPBT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 56 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 65 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| PPBT | SNTI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 78% | 1 day ago 78% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 77% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 75% | 1 day ago 83% |
| Advances ODDS (%) | 3 days ago 75% | 14 days ago 82% |
| Declines ODDS (%) | 16 days ago 89% | 2 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 89% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PPBT’s FA Score shows that 0 FA rating(s) are green while SNTI’s FA Score has 1 green FA rating(s).
- PPBT’s FA Score: 0 green, 5 red.
- SNTI’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PPBT’s TA Score shows that 5 TA indicator(s) are bullish while SNTI’s TA Score has 4 bullish TA indicator(s).
- PPBT’s TA Score: 5 bullish, 3 bearish.
- SNTI’s TA Score: 4 bullish, 4 bearish.
Price Growth
PPBT (@Biotechnology) experienced а +12.61% price change this week, while SNTI (@Biotechnology) price change was -20.97% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
PPBT is expected to report earnings on Nov 13, 2026.
SNTI is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PPBT and
Correlation & Price change
A.I.dvisor indicates that over the last year, PPBT has been loosely correlated with SNTI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PPBT jumps, then SNTI could also see price increases.
| Ticker / NAME | Correlation To PPBT | 1D Price Change % | ||
|---|---|---|---|---|
| PPBT | 100% | +11.94% | ||
| SNTI - PPBT | 57% Loosely correlated | +11.81% | ||
| ATOS - PPBT | 35% Loosely correlated | -5.14% | ||
| BCYC - PPBT | 32% Poorly correlated | N/A | ||
| APLM - PPBT | 31% Poorly correlated | -3.05% | ||
| CCCC - PPBT | 27% Poorly correlated | -3.67% | ||
More | ||||
SNTI and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNTI has been loosely correlated with PPBT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SNTI jumps, then PPBT could also see price increases.
| Ticker / NAME | Correlation To SNTI | 1D Price Change % | ||
|---|---|---|---|---|
| SNTI | 100% | +11.81% | ||
| PPBT - SNTI | 58% Loosely correlated | +11.94% | ||
| INBX - SNTI | 41% Loosely correlated | -0.02% | ||
| RXRX - SNTI | 35% Loosely correlated | +1.13% | ||
| DSGN - SNTI | 34% Loosely correlated | +1.13% | ||
| DYN - SNTI | 33% Poorly correlated | +0.39% | ||
More | ||||